Novavax Reports Narrower-Than-Expected Q3 Loss of $0.08 Per Share (NVAX)
Fri. November 06, 2009; Posted: 08:55 AM
Nov 06, 2009 (SmarTrend(R) News Watch via COMTEX) --
NVAX |
Quote |
Chart |
News |
PowerRating -- 11/5/2009 - Novavax (NASDAQ:NVAX) reported a Q3 net loss of $0.08, one cent better than consensus analyst estimates for a loss of $0.09. Revenue for the quarter rose 3.6% year-over-year to $201 thousand, coming out ahead of consensus analyst estimates of $30 thousand. President and CEO Dr. Rahul Singhvi said, "We are continuing to make rapid progress with each of our vaccine development programs which are targeting some of the world's most pressing public health problems. Our partnerships in the United States, Spain, Mexico and India are accelerating the development of our VLP based 2009 H1N1 pandemic influenza and seasonal influenza vaccines and enabling us to prepare for their commercial-scale production. In addition, we recently selected a vaccine candidate against Respiratory Syncytial Virus (RSV), the most common cause of lower respiratory tract infection in infants and young adults."
Write to Chip Brian at cbrian@tradethetrend.com
---------------------------------------------------------------------------------------------
SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.
Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html
For full details on Novavax Inc (NVAX)
click here. Novavax Inc (NVAX) has Short Term PowerRatings of 7. Details on Novavax Inc (NVAX) Short Term PowerRatings is available at
This Link.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index